Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes

Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes

PurposeMetabolic dysfunction-associated steatotic liver disease (MASLD) increases the risk of chronic kidney disease (CKD), compounding morbidity in patients with cirrhosis. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are disease-modifying agents in type 2 diabetes mellitus (T2DM) and CKD, bu...

Full description

Saved in:
Bibliographic Details
Main Authors: Alessandro Colletta, Katherine M. Cooper, Giuseppe Placentino, Deepika Devuni, Cosimo Colletta
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Endocrinology
Subjects:
Child-Turcotte-Pugh B cirrhosis
sodium-glucose cotransporter-2 inhibitors
metabolic dysfunction associated steatotic liver disease
type 2 diabetes mellitus
glomerular filtration rate
chronic kidney disease
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2025.1531295/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2025.1531295/full

Similar Items